Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Payment Information We accept all major credit cards

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Glucose Monitoring, Other

Bigfoot Hires Matt Rainville as CCO; Medtronic CY Q1 ’22 (FY Q4 ’22) Earnings Update; Pfizer’s NASH Combo Receives Fast Track Designation; ReShape and OpenLoop Collaboration for Virtual Weight Loss Coaching Program

Here is a brief preview of this blast: A series of cardiometabolic-related news items have been observed: Bigfoot announced it has appointed Matt Rainville (view LinkedIn) as CCO; Medtronic hosted its CY Q1 ’22 (FY Q4 ’22) earnings call (press release; slides); Pfizer announced FDA granted Fast Track designation to Pfizer’s ervogastat+clesacostat combination therapy for NASH; and ReShape LifeSciences and OpenLoop announced a collaboration for a nationwide launch of reshapecare. Below, FENIX provides highlights and insights for the respective new items.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.